Fig. 1 · Structure

Documents & Downloads

Deferasirox

Cat. No. A10293 CAS 201530-41-8

Iron chelator

Deferasirox is a rationally-designed oral iron chelator, also a cytochrome P450 3A4 inducer, Cytochrome P450 2C8 inhibitor, and Cytochrome P450 1A2 inhibitor.

In Stock

Publications for Deferasirox

2 publications citing this product

  1. Céline Moison, .et al. , Sci Adv, 2024, Mar 22;10(12):eadl4018 PMID: 38517966
  2. Jamie L. Dombach, .et al. , PLoS Pathog, 2020, Dec; 16(12): e1009119 PMID: 33290418

Free Aliquoting for Your Order

Tell us your preferred amount per vial. We’ll confirm the options.

Biological Activity

Bioactivity / Mechanism

Deferasirox is an iron-chelating research compound. In a sequential iron-loading and chelation gerbil model, oral deferasirox lowered stored cardiac and hepatic iron relative to sham chelation. In kidney-derived cells, iron co-treatment prevented deferasirox-associated mitochondrial swelling, emphasizing that iron binding and free-drug toxicity must be considered separately. [1,2]

Literature-reported observations and conditions; not Adooq-tested protocols or general treatment recommendations.

Deferasirox Research Summary

This section summarizes 1 in vitro study and 1 in vivo study of Deferasirox from 2 published references. In vitro models include opossum kidney (OK) proximal-tubule-derived cell line.

Deferasirox In Vitro Studies

In opossum kidney cells, deferasirox reduced 24-hour viability (IC50 246 µM) and caused rapid mitochondrial swelling at 200 µM while much of the membrane-potential-sensitive TMRM signal persisted. Iron prevented swelling; albumin also preserved viability. These high-concentration cellular findings identify a toxicity limitation and do not establish clinical exposure thresholds. [2]

Mitochondrial swelling and reduced viability in kidney-derived cells

Cell-based study · Opossum kidney (OK) proximal-tubule-derived cell line [2]

Deferasirox decreased 24-hour viability and caused rapid mitochondrial swelling. Mitochondria retained TMRM signal during acute swelling, while FCCP dissipated it. Other iron chelators did not reproduce the swelling. Iron co-treatment prevented swelling, and subsequent iron addition reversed it; albumin also reduced toxicity. These controls belong to the same cellular toxicity investigation.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
Cell viability relative to control after 24 hoursIC50 246 µM; n = 3 (replicate type not specified in caption)[2]
Mitochondrial morphology and membrane-potential-sensitive fluorescencequalitative response 200 µM DFX: marked swelling by 30 minutes with retained TMRM signal; most mitochondria remained energized at 3 hours[2]
Prevention and reversal of mitochondrial swellingqualitative rescue Iron(III) 200 µM with DFX 200 µM prevented swelling; iron added 10 minutes after DFX reversed swelling. Albumin 200 µM pretreatment for 5 minutes prevented swelling and preserved 24-hour viability (n = 3, mean ± SEM).[2]

Literature-Reported Treatment Conditions

Treatment concentration
200 µM for acute imaging; concentration-response series for the 24-hour viability IC50
Exposure duration
30 minutes for representative swelling images; tracking up to 3 hours; 24 hours for viability
Method
Cell exposure followed by live confocal imaging or Neutral Red viability assay
Co-treatment
Separate mechanistic controls: iron(III) 200 µM, albumin 200 µM, and FCCP 5 µM; deferoxamine and deferiprone were separate comparator treatments.
Reported limits
Vehicle composition for the selected Figure 1/6 cellular exposures and replicate type for the viability n = 3 are not specified in the selected main-text methods/captions. No other experiment’s vehicle is assigned.
Methods and source locations

Compound reported in the paper: Deferasirox; Compound label in the paper: DFX

Compound-level cellular observations; not validation of Adooq A10293 or a particular lot.

Figures 1a–h, 6a–c; Results: acute swelling, iron/albumin binding and recovery; Methods: Cell lines, Live imaging, Cell viability; Discussion

Cell viability relative to control after 24 hours: Neutral Red uptake; log(inhibitor) versus normalized response variable-slope analysis — Figure 1a caption; Methods: Cell viability

Mitochondrial morphology and membrane-potential-sensitive fluorescence: Live confocal imaging with TMRM and mitochondrial GFP; electron microscopy corroboration — Figure 1b–g and Results: acute mitochondrial swelling

Prevention and reversal of mitochondrial swelling: TMRM imaging and viability assay; albumin viability comparison by one-way ANOVA with Tukey multiple comparisons — Figure 6a–c caption; Results: iron/albumin binding and recovery

Deferasirox In Vivo Studies

In iron-overloaded gerbils, deferasirox at 100 mg/kg orally once daily, 5 days/week for 12 weeks, reduced cardiac iron content by 20.5% and liver iron content by 51.0% relative to sham chelation. Exercise performance did not significantly differ among groups. The study evaluated iron removal and did not provide a comprehensive toxicity assessment. [1]

Removal of stored cardiac and hepatic iron in iron-overloaded gerbils

Animal study · Iron-loaded female Mongolian gerbils (Meriones unguiculatus), initially 8–10 weeks old; sequential loading then chelation [1]

Compared with contemporaneous sham chelation, deferasirox reduced cardiac iron content by 20.5% and hepatic iron content by 51.0%. Exercise performance did not differ significantly among treatment groups, and cardiac fibrosis/hypertrophy did not improve significantly. The study assessed stored iron removal rather than prevention and did not establish clinical efficacy or a comprehensive safety profile.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
Cardiac iron content after 12 weeks versus sham chelationorgan iron content 0.171 ± 0.029 mg (deferasirox) versus 0.215 ± 0.028 mg (sham); mean ± SD; −20.5%; Results text P = 0.05[1]
Hepatic iron content after 12 weeks versus sham chelationorgan iron content 17.7 ± 4.5 mg (deferasirox) versus 36.1 ± 3.6 mg (sham); mean ± SD; −51.0%[1]
Exercise performance and cardiac histology after chelationlimiting findings No significant difference in exercise performance among treatment groups; reductions in cardiac fibrosis scores did not reach significance; no significant improvement in myocyte hypertrophy with deferasirox[1]

Conditions shared by the study groups

Route
Oral, mixed in peanut butter
Frequency
Once daily, 5 days/week
Treatment course
12 weeks
Vehicle
Plain peanut butter (approximately 0.15 mL/day stated for oral chelator administration)
Study groups and reported outcomes
Group / doseComparatorObserved resultReference
Deferasirox versus sham chelation
100 mg/kg per daily administration
Contemporaneous sham-chelated iron-loaded animals; separate deferiprone comparator (375 mg/kg/day divided into three doses)Cardiac iron content −20.5% and liver iron content −51.0% relative to sham. Exercise performance did not significantly differ among groups.[1]
Deferasirox versus sham chelation
Model: Iron-loaded female Mongolian gerbils; 8 allocated to deferasirox and 8 to sham
Reported limits: Exact sham feeding composition is not separately detailed. One anesthetic death occurred in the deferasirox group; endpoint-specific analyzed n remains unclear despite Table I N = 8.
Methods and source locations

Compound reported in the paper: Deferasirox; Compound label in the paper: Deferasirox

Preclinical compound-level efficacy under the reported gerbil regimen; not Adooq lot validation or human dosing guidance.

Methods: Chelation, Histology and organ iron assessment, Statistics; Results: Tables I/II and exercise assessment; Discussion limitations

Cardiac iron content after 12 weeks versus sham chelation: Quantitative tissue iron determination; ANOVA and Dunnett comparison; one-sided test for iron outcomes — Table I: Heart, Organ iron and % content change; Results paragraph after Table I; Methods: Statistics

Hepatic iron content after 12 weeks versus sham chelation: Quantitative tissue iron determination; Table I bold denotes P < 0.05 versus sham — Table I: Liver, Organ iron and % content change; Table I footnote

Exercise performance and cardiac histology after chelation: Treadmill running time; blinded histology scoring; ANOVA for exercise and specified nonparametric histology analysis — Results: EKG/exercise paragraphs and Table II discussion; Table II; Methods: Electrocardiography and exercise tests, Histology, Statistics

Deferasirox versus sham chelation · Abstract Methods; Methods: Chelation; Results opening paragraphs, Table I and exercise assessment

Specifications

Manufacturer Adooq Bioscience
Actions Inducer
CAS Number 201530-41-8
Applications Iron chelator
Formula C21H15N3O4
Molecular Weight 373.36
Synonyms ICL-670; ICL-670A; CGP-72670
SMILES
OC(=O)c1ccc(cc1)-n1nc(-c2ccccc2O)nc1-c1ccccc1O

Storage & Solubility

In Vitro Solubility

Reported Solubility

SolventReported Solubility
DMSO 64 mg/mL (171.42 mM)
Water Insoluble
Ethanol 2 mg/mL

Preparing Stock Solutions

Stock preparation is unavailable for this product molecular weight.

Calculated stock concentrations do not establish solvent solubility. Refer to the reported solubility data for experimental guidance.

In Vivo Preparation

Concentration
3.5 mg/mL
Vehicle
5% DMSO+40% PEG 300+5%Tween 80 +50 % H2O

Storage

Store powder at -20°C, keep desiccated.
In powder form, the chemical is stable for 36 months.
In solution, store at -20°C and use within 1 month to prevent loss of potency. Aliquot to avoid multiple freeze/thaw cycles.

Deferasirox Research References

  1. [1] Wood JC, Otto-Duessel M, Gonzalez I, et al. Deferasirox and deferiprone remove cardiac iron in the iron-overloaded gerbil Translational research : the journal of laboratory and clinical medicine (2006). PMID: 17145573 DOI: 10.1016/j.trsl.2006.05.005 Source material
  2. [2] Gottwald EM, Schuh CD, Drücker P, et al. The iron chelator Deferasirox causes severe mitochondrial swelling without depolarization due to a specific effect on inner membrane permeability Scientific reports (2020). PMID: 32005861 DOI: 10.1038/s41598-020-58386-9 Source material

Publications

2 publications citing this product

  1. Céline Moison, .et al. , Sci Adv, 2024, Mar 22;10(12):eadl4018 PMID: 38517966
  2. Jamie L. Dombach, .et al. , PLoS Pathog, 2020, Dec; 16(12): e1009119 PMID: 33290418

Added to your cart

View Cart Checkout
Loading...